A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Disc Medicine, Inc
Study ID
NCT07187973
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DISC-3405 — DRUG
    DISC-3405 is administered subcutaneously.

Study Details

This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

Key Dates

Start date
Jan 6, 2026
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Within-participant dose escalation
    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405.

Primary Outcome Measure

Safety and tolerability of DISC-3405 administration in participants with SCD [ Time Frame: Up to 36 weeks ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Emily Warner
[email protected]
205-996-1735
Emily Burke
[email protected]
205-996-2205
Julie Kanter, MD (PRINCIPAL_INVESTIGATOR)
Emory UniversityAtlantaGeorgia30322
Sonjile James
[email protected]
404-778-6470
Brittney Schwebach
[email protected]
470-588-6670
Fuad El Rassi, MD (PRINCIPAL_INVESTIGATOR)
Augusta UniversityAugustaGeorgia30912
Latanya Bowman
[email protected]
Sharon Jones
[email protected]
706-721-2172
Abdullah Kutlar, MD (PRINCIPAL_INVESTIGATOR)
Innovative Hematology - Indiana Hemophilia & Thrombosis CenterIndianapolisIndiana46260
Nehal Sheth
[email protected]
317-871-0000
Neelam Thrukal
[email protected]
Amro Elshoury, MD (PRINCIPAL_INVESTIGATOR)
Mount Sinai HospitalNew YorkNew York10029
Mitali Pradhan
[email protected]
201-423-3585
Jordan Bellis
[email protected]
646-668-6642
Susanna Curtis, MD, PhD (PRINCIPAL_INVESTIGATOR)
Duke University Medical CenterDurhamNorth Carolina27708
Mary Beth Summers
[email protected]
919-613-4657
Lindsey Ford
[email protected]
John Strouse (PRINCIPAL_INVESTIGATOR)
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Kara McClure
[email protected]
513-803-7271
Amy Shova
[email protected]
513-803-1917
Charles Quinn, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Sickle cell disease
By research site
University of Alabama at Birmingham· Birmingham, ALEmory University· Atlanta, GAAugusta University· Augusta, GAInnovative Hematology - Indiana Hemophilia & Thrombosis Center· Indianapolis, INMount Sinai Hospital· New York, NYDuke University Medical Center· Durham, NC

Related Studies